Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital.
Condition: Plaque Psoriasis
MeSH terms: Psoriasis
Study type: Interventional
Phase: Phase 4

Summary: 
      Psoriasis is one of the most common immune-mediated inflammatory disorders characterized by a
      chronic course. It affects approximately 2-3% of the world's population Psoriasis may be
      provoked by environmental factors in patients with genetic predispositions. Psoriasis is
      phenotypically characterized by thickened, red, scaly plaques and systemic inflammation, it
      is also associated with multiple comorbidities, such as cardiovascular disease, stroke,
      hypertension, metabolic diseases, chronic kidney disease, and joint destruction. Psoriasis is
      pathogenically driven by proinflammatory cytokines and mediated by T and dendritic cells.
      Inflammatory myeloid dendritic cells release interleukin (IL) 23 and IL-12 to activate
      IL-17-producing T cells, Th1 cells, and Th22 cells to produce psoriatic cytokines like IL-17,
      interferon (IFN) γ, TNF, and IL-22. These cytokines mediate the effects on keratinocytes.
      Secukinumab is a recombinant human monoclonal antibody that specifically binds to a
      proinflammatory cytokine released by T-helper-17 (Th17) cells, IL-17A. It blocks its binding
      with IL-17R and the expression of cytokines. This blockade normalizes the inflammatory
      processes and combats epidermal hyperproliferation, T-cell infiltration, and exaggerated
      expression of pathogenic genes.
    

Detailed description: 
      Plaque psoriasis is a chronic autoimmune skin disorder characterized by the formation of
      thick, scaly plaques on the skin surface. It affects millions of individuals worldwide and
      significantly impacts their quality of life. While several treatment options exist, a
      substantial number of patients with moderate to severe plaque psoriasis fail to achieve
      satisfactory results or experience intolerable side effects with conventional therapies.

      Psoriasis is pathogenically driven by proinflammatory cytokines and mediated by T cells and
      dendritic cells. In recent years, the advent of biologic agents targeting specific immune
      pathways has revolutionized the management of psoriasis. Secukinumab, a fully human
      monoclonal antibody that selectively inhibits interleukin-17A, has shown promising results in
      randomized controlled trials and real-world studies. However, there remains a need to assess
      the real-world effectiveness and safety of Secukinumab in routine clinical practice,
      particularly in patients with moderate to severe plaque psoriasis who may have diverse
      characteristics and treatment histories.

      This observational study aims to evaluate the real-world effectiveness and safety of
      Secukinumab in patients with moderate to severe plaque psoriasis. By collecting data from a
      diverse patient population in routine clinical settings, we aim to provide valuable insights
      into the outcomes and experiences of patients receiving Secukinumab outside the controlled
      environment of clinical trials.
    

Intervention name(s): Secukinumab Injection
Intervention type(s): Drug
Intervention description(s): Injection Secukinumab 150mg subcutaneously will be administered at weeks 0, 1, 2, 3, 4, and then monthly for 5 months.
Other intervention name(s): Cosentyx
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Plaque Psoriasis; Secukinumab Injection; Outcome